Your session is about to expire
← Back to Search
Other
VQW-765 for Performance Anxiety
Phase 2
Waitlist Available
Research Sponsored by Vanda Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Ability and willingness to provide written informed consent.
Sufficiently fluent in English to participate in the trial.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Awards & highlights
Study Summary
This trial will compare the effects of VQW-765 to a placebo in people with performance anxiety. The trial is double-blind, meaning that neither the participants nor the researchers will know who is receiving the active drug or the placebo.
Eligible Conditions
- Performance Anxiety
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 day
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Subjective Units of Distress Scale (SUDS)
Secondary outcome measures
Assessment of safety and tolerability of a single dose of VQW-765, as measured by spontaneous reporting of adverse events (AEs)
Clinician Global Impression of Change (CGI-C) scale at visit 2
Patient Global Impression of Change (PGI-C) scale at visit 2
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: VQW-765Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
Vanda PharmaceuticalsLead Sponsor
60 Previous Clinical Trials
24,128 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger